Published in Ned Tijdschr Geneeskd on February 15, 1997
[Effective removal of certain skin pigment spots (lentigenes) using the Q-switched ruby laser]. Ned Tijdschr Geneeskd (1997) 0.75
The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol (1999) 1.73
Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol (2001) 1.68
[Turning white overnight, is it possible?]. Ned Tijdschr Geneeskd (1993) 1.61
Grafting of venous leg ulcers. An intraindividual comparison between cultured skin equivalents and full-thickness skin punch grafts. J Am Acad Dermatol (1991) 1.45
Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest (2000) 1.39
Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39
Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol (1993) 1.35
Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol (1996) 1.35
Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol (1999) 1.25
Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol (1993) 1.19
A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol (1998) 1.16
Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol (1998) 1.13
A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol (1993) 1.08
Extracellular matrix characterization during healing of full-thickness wounds treated with a collagen/elastin dermal substitute shows improved skin regeneration in pigs. J Histochem Cytochem (1996) 1.04
A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol (2009) 1.03
Large-scale cultivation of human melanocytes using collagen-coated Sephadex beads (cytodex 3). J Invest Dermatol (1989) 1.03
Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res (1992) 1.02
Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. In Vitro Cell Dev Biol Anim (1997) 1.00
Phagocytosis by normal human melanocytes in vitro. Exp Cell Res (1993) 0.95
Quantification of UV-induced erythema with a portable computer controlled chromameter. Photodermatol (1986) 0.95
Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production. J Eur Acad Dermatol Venereol (2008) 0.95
Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. J Am Acad Dermatol (1995) 0.94
PIG3V, an immortalized human vitiligo melanocyte cell line, expresses dilated endoplasmic reticulum. In Vitro Cell Dev Biol Anim (2000) 0.93
Neurofibromatosis and hypertelorism. Arch Dermatol (1984) 0.91
Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J Eur Acad Dermatol Venereol (2007) 0.91
Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol (2001) 0.90
Infrared hyperthermia and psoriasis. Arch Dermatol Res (1987) 0.89
Production of catecholamines in the human epidermis. Biochem Biophys Res Commun (1992) 0.89
Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol (2000) 0.88
Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol (2007) 0.88
Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol (2000) 0.86
Serum and urine concentrations of 5-methoxypsoralen after oral administration. Br J Dermatol (1981) 0.85
Albinism: phenotype or genotype? Doc Ophthalmol (1983) 0.85
Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol (2000) 0.84
Reduced wound contraction and scar formation in punch biopsy wounds. Native collagen dermal substitutes. A clinical study. Br J Dermatol (1995) 0.84
Pigmented lesions of the tongue in heroin addicts--fixed drug eruption. Br J Dermatol (1983) 0.84
Dermatitis as side-effect of long-term metoprolol. Lancet (1979) 0.84
Adherence, proliferation and collagen turnover by human fibroblasts seeded into different types of collagen sponges. Cell Tissue Res (1995) 0.83
Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection. Anal Biochem (1990) 0.83
Trigeminal trophic syndrome: a successful treatment with transcutaneous electrical stimulation. Br J Dermatol (1983) 0.82
Dermal substitutes for full-thickness wounds in a one-stage grafting model. Wound Repair Regen (1993) 0.82
The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol (1995) 0.81
Quantitative and objective evaluation of wound debriding properties of collagenase and fibrinolysin/desoxyribonuclease in a necrotic ulcer animal model. Arch Dermatol Res (1998) 0.81
Melanin-related metabolites as markers of the skin pigmentary system. J Invest Dermatol (1987) 0.81
Progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names? J Eur Acad Dermatol Venereol (2006) 0.80
A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. Br J Dermatol (1995) 0.80
Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res (1985) 0.80
Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed (2006) 0.80
Hereditary congenital hypopigmented and hyperpigmented macules. Arch Dermatol (1978) 0.80
Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol (1997) 0.80
Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol (1998) 0.79
Laser treatment for further depigmentation in vitiligo. Int J Dermatol (1997) 0.79
Organotypic culture of human skin to study melanocyte migration. Pigment Cell Res (1994) 0.79
L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology (1994) 0.79
Effect of nitric oxide on the adhesion of human melanocytes to extracellular matrix components. J Pathol (1997) 0.79
Expression of different immunological markers by cultured human melanocytes. Arch Dermatol Res (1993) 0.79
Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. J Invest Dermatol (1992) 0.79
HLA associations in vitiligo patients in the Dutch population. Dis Markers (1993) 0.78
Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen. Br J Dermatol (1985) 0.78
Catechol-O-methyltransferase in vitiligo. Arch Dermatol Res (1994) 0.78
Blue-red macules and pseudoatrophic macules: additional cutaneous signs in neurofibromatosis. Arch Dermatol (1982) 0.78
[Toxicological aspects and health risks associated with hydroquinone in skin bleaching formula]. Ned Tijdschr Geneeskd (2004) 0.78
The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann N Y Acad Sci (1999) 0.78
Hypertelorism in neurofibromatosis. Neuropediatrics (1986) 0.78
In vitro tissue-digesting properties of krill enzymes compared with fibrinolysin/DNAse, papain and placebo. Int J Biochem Cell Biol (1997) 0.77
Basic fibroblast growth factor promotes melanin synthesis by melanocytes. Arch Dermatol Res (1996) 0.77
O-methylation of L-dopa in melanin metabolism and the presence of catechol-O-methyltransferase in melanocytes. Pigment Cell Res (1994) 0.77
PUVA for vitiligo and skin cancer. Clin Exp Dermatol (1997) 0.77
Anti-oxidant defence mechanism in vitiliginous skin increases with skin type. J Eur Acad Dermatol Venereol (2011) 0.77
Efficient debridement of necrotic wounds using proteolytic enzymes derived from Antarctic krill: a double-blind, placebo-controlled study in a standardized animal wound model. Wound Repair Regen (1999) 0.76
Stromal cells from subcutaneous adipose tissue seeded in a native collagen/elastin dermal substitute reduce wound contraction in full thickness skin defects. Lab Invest (1995) 0.76
Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. Br J Dermatol (2002) 0.76
Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement. Immunobiology (1998) 0.76
Treatment of vasculitis with chlorpromazine and dapsone. Arch Dermatol Res (1985) 0.75
Venous ulceration. Lancet (1993) 0.75
Photoprotection in vitiligo and normal skin. Acta Derm Venereol (1998) 0.75
[Minor symptoms in family medicine; chloasma or 'pregnancy mask']. Ned Tijdschr Geneeskd (1995) 0.75
Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol (1994) 0.75
Vitiligo--a window in the darkness. Dermatology (1995) 0.75
Multifocal hematogenous osteomyelitis in an adult treated with corticosteroids. Arch Orthop Trauma Surg (1982) 0.75
Controlled double-blind trial of fibrinolysin-desoxyribonuclease (Elase) solution in patients with chronic leg ulcers who are treated before autologous skin grafting. J Am Acad Dermatol (1987) 0.75
Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol (1987) 0.75
Linear dermo-epidermal IgA deposition in bullous pemphigoid. Acta Derm Venereol (1979) 0.75
[Vitiligo]. Ned Tijdschr Geneeskd (1997) 0.75
Langerhans' cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol (1986) 0.75
[Wounds and wound healing]. TVZ (1991) 0.75
A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria. J Int Med Res (1989) 0.75
Management of vitiligo. Results of a questionnaire among dermatologists in The Netherlands. Int J Dermatol (1999) 0.75
Vitiligo: news in surgical treatment. J Eur Acad Dermatol Venereol (2001) 0.75
The spectral stability of several sunscreening agents on stratum corneum sheets. Int J Cosmet Sci (1987) 0.75
[Vitiligo]. Ned Tijdschr Geneeskd (1984) 0.75
The morphological details of globular keratohyalin granules. J Cutan Pathol (1986) 0.75
A possible dysfunction of melanosome transfer in leprosy: an electron-microscopic study. Acta Derm Venereol (1977) 0.75
Evidence for alpha-MSH binding sites on human scalp hair follicles: preliminary results. Pigment Cell Res (1991) 0.75
[Growth factors and healing]. Phlebologie (1990) 0.75
[Transplantation of autologous skin biopsies: an effective clinical treatment of leg ulcer]. Ned Tijdschr Geneeskd (1986) 0.75
Possibilities of liposomes as dynamic dosage form in dermatology. Med Hypotheses (1985) 0.75
[Exogenous ochronosis, a little-known side effect of hydroquinone-containing ointments]. Ned Tijdschr Geneeskd (1992) 0.75
The morphology of keratohyalin granules in orthokeratotic and parakeratotic skin and oral mucosa. Int J Dermatol (1987) 0.75
[Application of growth factors in wound healing: fiction or reality?]. Ned Tijdschr Geneeskd (1989) 0.75